Legarda Mario A, Cejalvo María J, de la Rubia Javier
Hematology Department, University Hospital Doctor Peset, 46017 Valencia, Spain.
Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, 46017 Valencia, Spain.
Cancers (Basel). 2020 Nov 30;12(12):3576. doi: 10.3390/cancers12123576.
In the past 20 years, few diseases have seen as great progress in their treatment as multiple myeloma. With the approval of many new drugs and the limited availability of clinical trials comparing head-to-head the different possible combinations, the choice of the best treatments at each stage of the disease becomes complex as well as crucial since multiple myeloma remains incurable. This article presents a general description of the novelties of the whole treatment of multiple myeloma, from induction in the newly diagnosed patient through the role of hematopoietic stem cell transplantation and maintenance treatment until early and late relapses, including a section on recently approved drugs as well as novel drugs and immunotherapy in advanced stages of research, and that will surely play a relevant role in the treatment of this devastating disease in the coming years.
在过去20年里，很少有疾病在治疗方面取得像多发性骨髓瘤那样大的进展。随着许多新药获批，以及直接比较不同可能组合的临床试验数量有限，由于多发性骨髓瘤仍无法治愈，因此在疾病的每个阶段选择最佳治疗方案既复杂又关键。本文全面介绍了多发性骨髓瘤整体治疗的新进展，从新诊断患者的诱导治疗，到造血干细胞移植和维持治疗的作用，直至早期和晚期复发，其中还包括一部分关于近期获批药物以及处于研究后期的新型药物和免疫疗法的内容，这些在未来几年肯定会在这种毁灭性疾病的治疗中发挥重要作用。
